Overview

A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of NMOSD.
Phase:
PHASE1
Details
Lead Sponsor:
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Treatments:
Mycophenolic Acid